Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Children with a rare genetic disease that is particularly prevalent among Quebecers could see their lives changed thanks to a new treatment developed by researchers at the McGill University Health Centre.

The McGill team is leading North American efforts to develop a drug for nephropathic cystinosis, which is 10 times more prevalent in Quebec than elsewhere in the world. Without treatment, children with the disorder require a kidney transplant, and few survive beyond the age of 30.

Researchers say the disease was brought to Quebec about 200 years ago by an immigrant Irish family.

Story continues below advertisement

Sophie Laferriere, whose 9-year-old son Nolan has the disease, described in an interview the toll it has taken.

“From the age of 5 months, Nolan stopped growing .... He didn’t try to move around,” she said. “At around 6 months, he was eating very little and continuously vomiting.”

It was soon afterwards that physicians at the Montreal Children’s Hospital, part of the McGill centre, diagnosed nephropathic cystinosis. It is caused by what are known as “nonsense mutations,” an error in the gene code that causes cells to stop producing a protein.

That in turn leads to the build-up of an amino acid and kidney deterioration.

From the age of 8 months to 4 years, Nolan had to be fed through a tube. Today, the boy is able to feed himself and is in Grade 3. But his parents and school officials have to inject him with 150 doses a week of electrolyte medication.

It is almost a full-time job for his parents, who have not had an uninterrupted night of sleep for years.

“His kidneys systematically expel the vitamins he ingests, so we have to inject electrolytes to avoid deficiencies, in addition to injections of drugs to slow the disease,” Laferriere said.

Story continues below advertisement

Nolan will now be part of a clinical trial led by Dr. Paul Goodyer, a pediatric nephrologist at the Montreal Children’s Hospital. Goodyer said the drug being tested tricks the cell into overlooking the mistake in the gene code so protein production continues. He said the non-toxic drug, developed with a $2 million contribution from Quebec’s genomics research agency, could provide a cure.

“My hope is that he can live as long as you and me,” Goodyer said of Nolan.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies